Z-Ile-Leu-aldehyde (Z-IL-CHO, GSI-XII, γ-Secretase inhibitor XII) is a potent gamma-secretase and Notch signaling inhibitor.

ZIKV inhibitor K22 is a small molecule that exerts a potent antiviral activity against a broad range of coronaviruses by targeting membrane-bound viral RNA replication, effectively inhibits ZIKV with IC50 of 2.1 uM

Zicronapine is an antipsychotic agent that shows potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors, exhibits monoaminergic activity and has a multi-receptorial profile..

ZGN-1061 (Aclimostat) is a novel potent, selective Methionine aminopeptidase 2 (MetAP2) inhibitor being investigated for treatment of diabetes and obesity.

ZD-7288 (ICI-D 7288) is a selective hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker.

ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.

ZBMA-1 is a potent HIV-1 replication inhibitor (IC50=1.01 uM) that efficiently protects APOBEC3G protein by targeting Vif-APOBEC3G complex.

Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.

Zanapezil (TAK-147) is a potent, selective acetylcholinesterase (AChE) inhibitor with IC50 of 97.7 nM.

Z-590 is a potent inhibitor of macrophage migration inhibitory factor (MIF) tautomerase activity.

Z-505 hydrochloride is a novel, orally active ghrelin (GHSR1a) agonist with EC50 of 2.08 nM and 5.46 nM for rat and mouse GHSR1a, respectively.

YZ129 (YZ-129) is a small molecule inhibitor of HSP90-Calcineurin-NFAT pathway, suppresses TG-induced NFAT nuclear translocation in HeLa cellswith IC50 of 820 nM.

YU142670 is a highly specific, soluble OCRL/INPP5B inhibitor that directly interacts with the catalytic domain of INPP5B.

YPC-22026, a metabolically stable derivative of YPC-21661, is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143), inhibits the binding of ZNF143 to DNA.

YPC-21661 is a novel small molecule inhibitor of the transcription factor Zinc-finger protein 143 (ZNF143).

Yohimbine is an indole alkaloid that has high affinity for the α2-adrenergic receptors with Ki of 1 nM for α2A, α2B and α2C.

YM116 is a potent CYP17A1 (17,20-lyase) inhibitor with IC50 with Ki of 0.38 nM, inhibits C17-20 lyase activity in human testicular microsomes with IC50 of 4.2 nM.

YM 254890 is a selective Gq signaling inhibitor that strongly inhibits intracellular calcium ion mobilization and serum response element (SRE)-mediated transcription stimulated by several receptors coupled to Gq, but not those coupled to Gi, Gs, or G15.

YLC2-155 is a novel potent HIV-1 reverse transcriptase (RT) inhibitor that inhibits both polymerase (IC50=2.6 uM) and RNase H function (IC50=0.65 uM) of RT.

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

YKL-1-116 is a potent, selective and covalent inhibitor of CDK7 that does not inhibit other CDKs.

YK5 is a small molecule inhibitor of Hsp70 and Hsc70, induces the degradation of HER2, Raf-1, and Akt kinases, also induces apoptosis in the SKBr3 breast cancer cells..

YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIR-819 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.6 uM against YTA48P virus with no significant cytotoxicity (CC50=33 uM).

YIL-781 Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM).

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YHO-13351 is an orally available prodrug of YHO-13177, which can specifically reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.

YH12852 is a potent, highly selective 5-HT4 receptor agonist with pKi of 10.3, exhibits more potent agonistic activity (pEC50=11.4) than both tegaserod and prucalopride.